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Highlights 
•Compared advanced NSCLC phase III trials: pemetrexed–cisplatin with or without pem 
maintenance. 
•4 cycles pem–cis followed by pem maintenance improves survival over 6 cycles pem–cis. 
•Longer exposure to pem–cis or maintenance pem increases some toxicities, but overall incidence 
low. 
Abstract 
Objectives 
Two phase III trials of advanced NSCLC patients were compared to examine relative efficacy and 
safety of differing treatment regimens. The JMDB trial investigated first-line pemetrexed–cisplatin 
(pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2 every 21 days; maximum: 6 cycles). The 
PARAMOUNT phase III trial compared maintenance pemetrexed versus placebo after patients with 
nonsquamous NSCLC completed 4 cycles of first-line pemetrexed–cisplatin without disease 
progression. 
Methods 
Overall survival (OS) and progression-free survival (PFS), analyzed by Kaplan–Meier and Cox 
methods, and toxicity rates were compared between the PARAMOUNT arms and a selected 
homogeneous population from JMDB: 346 patients with disease and prior treatment 
characteristics matching the PARAMOUNT population. 
Results 
Outcomes for the PARAMOUNT placebo arm were similar to the JMDB homogeneous group 
(median PFS: 5.6 versus 6.2 months, p = 0.117, HR = 1.16; median OS: 14.0 versus 14.2 months, 
p = 0.979, HR = 1.00). The PARAMOUNT maintenance pemetrexed group had statistically superior 
efficacy compared with the JMDB homogeneous group (median PFS: 7.5 versus 6.2 months, 
p < 0.00001, HR = 0.66; median OS: 16.9 versus 14.2 months, p = 0.003, HR = 0.75). Patients who 
received pemetrexed maintenance (median 4 cycles, range 1–44) following 4 cycles of 
pemetrexed–cisplatin exhibited a higher incidence of drug-related serious adverse events 
compared with JMDB patients (median 6 cycles of pemetrexed–cisplatin) (10.6% versus 2.9%); 
grade 3/4 fatigue and renal toxicity were also higher in the pemetrexed arm of PARAMOUNT. 
Conclusions 
The across-trial comparison of a relevant JMDB study population with the two arms of the 
PARAMOUNT study supported the efficacy of the pemetrexed continuation maintenance strategy 
and suggested the results are not influenced by limiting the pemetrexed–cisplatin induction 
treatment to four cycles. Although longer exposure to pemetrexed–cisplatin or maintenance 
pemetrexed increased some toxicities, the overall incidence remained low, underscoring the 
relative safety of these treatment regimens. 
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1. Introduction 
Lung cancer is the most common type of cancer globally and the leading cause of cancer-related 
deaths for both men and women in the United States. Approximately 85% of lung cancers are non-
small cell (NSCLC), and more than 70% of patients with NSCLC present with inoperable, locally 
advanced (Stage IIIB) or metastatic (Stage IV) disease [1]. 
Platinum-based doublet therapy is recommended for first-line treatment of patients with 
advanced NSCLC, with cisplatin preferred to carboplatin in Europe [2], [3] and [4]. In a large phase 
III study of pemetrexed–cisplatin versus gemcitabine–cisplatin, in patients with advanced NSCLC of 
all histologies (referred to here as “JMDB study”), a pre-specified subgroup analysis in patients 
with nonsquamous NSCLC showed pemetrexed–cisplatin to have superior survival compared with 
gemcitabine–cisplatin [5]. This differential efficacy based on histology, as well as a significant 
treatment-by-histology interaction for pemetrexed, was consistently detected across multiple 
studies [6]. These results led to a recommendation of pemetrexed–cisplatin for first-line treatment 
of patients with advanced nonsquamous NSCLC [2], [3] and [4]. 
Subsequently, pemetrexed versus placebo was investigated as switch maintenance treatment, and 
significant improvements of progression-free survival (PFS) and overall survival (OS) after 
induction with a non-pemetrexed platinum doublet were shown [7]. More recently, the 
PARAMOUNT study examined pemetrexed continuation maintenance therapy following four 
cycles of pemetrexed–cisplatin as induction treatment and found significantly improved PFS and 
OS when administered to non-progressing patients with advanced, nonsquamous NSCLC 
[8] and [9]. Current guidelines recommend maintenance single-agent pemetrexed for patients 
with stable disease (SD) or tumor response after four cycles of platinum-containing induction 
therapy [2], [3] and [4]. 
When evaluating results from trials testing the maintenance hypothesis, some might comment 
that patients received only four courses of induction treatment, whereas in clinical practice and in 
many guidelines, up to six cycles are recommended when the patient achieves objective response 
(and four cycles if patient achieves only disease stabilization). Consequently, it could be 
questioned if two more cycles of combination platinum chemotherapy could have accomplished 
the same outcome as the maintenance therapy. 
This report compares the efficacy and safety results of patients with nonsquamous NSCLC treated 
with pemetrexed–cisplatin in the JMDB study with the two arms of the PARAMOUNT study. The 
PARAMOUNT placebo arm/JMDB population comparison will evaluate whether the first-line 
pemetrexed–cisplatin results are consistent between studies, and provide information regarding 
four versus six cycles of first-line pemetrexed–cisplatin. The JMDB population and the 
PARAMOUNT pemetrexed continuation maintenance arm comparison will investigate longer first-
line treatment followed by the option of second-line therapy at tumor progression, versus four 
cycles of induction therapy followed by continuation maintenance therapy and optional second-
line treatment at progression. The goal of both comparisons is to further elucidate optimal 
treatments and durations for patients with advanced nonsquamous NSCLC. 
2. Methods 
2.1. Patients and study design 
Detailed descriptions of both trials have been previously published [5], [8] and [9]. In brief, the 
PARAMOUNT study enrolled 939 chemotherapy-naïve patients primarily from European centers 
with advanced (stage IIIB or IV) nonsquamous NSCLC to receive four 21-day cycles of pemetrexed 
(500 mg/m2) and cisplatin (75 mg/m2) induction therapy. 539 patients who completed four cycles 
of induction therapy with documented radiographic evidence of partial (PR) or complete (CR) 
tumor response or SD, and who had Eastern Cooperative Oncology Group (ECOG) performance 
status (PS) of 0 or 1, were then randomly assigned (2:1 ratio) to receive maintenance therapy with 
pemetrexed (500 mg/m2) (n = 359) or placebo (9% sodium chloride) (n = 180). All randomized 
patients were included in the previously reported efficacy and safety analysis populations 
[8] and [9] and are included in the analyses described here. 
The JMDB first-line study included 1725 chemotherapy-naïve advanced (stage IIIB or IV) NSCLC 
patients of any histology [5]. A subset of these patients was identified that matched the key 
criteria of the patient population of the PARAMOUNT study: nonsquamous NSCLC, treated with at 
least four 21-day cycles of pemetrexed (500 mg/m2) and cisplatin (75 mg/m2), without ECOG PS >1 
prior to completing the fourth cycle, and without radiologic evidence of disease progression at the 
time of completing the fourth cycle. Of the 378 patients identified, 346 were included in this 
selected homogeneous patient population used for the analyses here. The other 32 patients were 
not included because they had been enrolled at Taiwanese or Korean centers, and the 
PARAMOUNT comparator population did not include patients from those geographic areas [8]. 
Patients from this geography have a better prognosis than patients from non-East Asian 
geographies, with nearly double the median survival [10] and [11]. Neither study determined the 
EGFR mutation status of the patients. 
For all randomized patients in PARAMOUNT, and for all patients in the JMDB homogeneous 
population, tumor assessments took place every six weeks according to both study protocols. 
After treatment discontinuation in JMDB, non-progressing patients continued to undergo tumor 
assessment at the same frequency (every six weeks) as patients on maintenance treatment in the 
PARAMOUNT study. 
2.2. Statistical analyses 
The post hoc meta-analysis presented entails a cross-trial comparison of PARAMOUNT and JMDB. 
All analyses were run for the two randomized arms of PARAMOUNT in comparison to the selected 
homogeneous population from JMDB. Detailed descriptions of the primary statistical analyses of 
both studies have been previously published [5], [8] and [9]. The following analyses were carried 
out for the three treatment groups: Kaplan–Meier estimates (including medians) for PFS and OS; 
Cox hazard ratio estimates [with p-values and 95% confidence intervals (CIs)] for PFS and OS. 
Frequencies and percentages of key baseline characteristics, post-study treatment usage, and 
adverse events (AEs), serious AEs, and graded AEs were calculated. Both studies were registered 
with ClinicalTrials.gov: NCT00087711 (JMDB) and NCT00789373 (PARAMOUNT). 
3. Results 
The baseline and disease characteristics of the JMDB homogeneous population are similar to 
those published for the complete JMDB study population [5] and similar to those of the two 
PARAMOUNT arms (Table 1). Some notable differences between the PARAMOUNT and JMDB 
populations were the NSCLC stage percentages (stage IIIB NSCLC: 9% versus 21%, respectively), 
“Other or indeterminate histology” (approximately 6% versus 17%, respectively), and smoking 
status “Unknown” (1% versus 35%, respectively). In general, the distribution of patient and disease 
characteristics represented in these three groups is similar to that seen in other recent phase III 
studies [7], [12], [13] and [14]. 
Table 1.  
Baseline patient and disease characteristics.a 
 
PARAMOUNT 
pemetrexed arm 
(n = 359) 
PARAMOUNT 
placebo arm 
(n = 180) 
JMDB 
homogeneous 
population 
(n = 346) 
Median age, years 60 62 60 
Age <70/≥70 85.5/14.5 77.8/22.2 85.5/14.2 
Female/male (%) 44.0/56.0 37.8/62.2 36.7/63.3 
ECOG performance status 0/1 
(%)b 
31.5/68.5 33.3/66.7 37.9/62.1 
Stage IIIB/IV (%) 8.6/91.4 10.0/90.0 21.4/78.6 
Adenocarcinoma/large 
cell/other or indeterminate (%)b 
86.4/6.7/7.0 89.4/6.7/3.9 71.1/11.6/17.3 
Smoking: ever/never/unknown 
(%) 
76.3/23.1/0.6 80.0/18.9/1.1 51.4/13.3/35.3 
Abbreviation. ECOG: Eastern Cooperative Oncology Group. 
a 
Percentages not totaling 100% are due to rounding or missing data. PARAMOUNT data 
were derived from the initial database lock. 
b 
The subcategory of “Other” represents patients with a primary diagnosis of NSCLC whose 
disease did not clearly qualify as adenocarcinoma or large cell carcinoma and includes 
NSCLC not otherwise specified, poorly differentiated, and adenocarcinoma, mucinous. 
Table options 
A comparison of dosage administration between the two studies (Table 2) reflects the differences 
expected due to study design. Among the homogeneous JMDB population, the median number of 
pemetrexed–cisplatin cycles was 6 (mean 5.5), with about 72% of the homogeneous population 
completing 6 cycles, 10% completing 5 cycles, and 18% completing 4 cycles. Patients randomized 
to maintenance in PARAMOUNT received 4 cycles of pemetrexed–cisplatin induction as per 
protocol. The two PARAMOUNT arms subsequently received maintenance cycles, with 
pemetrexed arm patients received a median of 4 cycles (range 1–44) and mean of 8 cycles, and 
the placebo arm patients received a median of 4 cycles (range 1–38) and mean of 5 cycles. 
Table 2.  
Treatment administration. 
 
PARAMOUNT 
pemetrexed arma 
(n = 359) 
PARAMOUNT 
placebo arma 
(n = 180) 
JMDB 
homogeneous 
population 
(n = 346)b 
Patients treated 359 180 346 
Median number of pem–cis 
cycles (range) 
4 (4) 4 (4)c 6 (4–6)d 
Mean number of pem–cis 
cycles 
4.0 4.0 5.5 
Patients completing ≥4 pem–
cis cycles, n (%) 
359 (100) 179 (99.4) 346 (100) 
Patients completing ≥5 pem–
cis cycles, n (%) 
NA NA 285 (82.4) 
Patients completing 6 pem–
cis cycles, n (%) 
NA NA 250 (72.3)d 
Median number of pem 
maintenance cycles (range) 
4 (1–44) 4 (1–38) NA 
 PARAMOUNT 
pemetrexed arma 
(n = 359) 
PARAMOUNT 
placebo arma 
(n = 180) 
JMDB 
homogeneous 
population 
(n = 346)b 
Mean number of pem 
maintenance cycles 
(standard deviation) 
7.9 (8.3) 5.0 (5.2) NA 
Abbreviations. Cis = cisplatin; pem = pemetrexed. 
A The PARAMOUNT data summarize induction phase dose administration, that is, 
treatment prior to randomization to the maintenance phase. Four cycles of pemetrexed–
cisplatin were stipulated by protocol. 
B The JMDB trial stipulated a maximum of 6 cycles pemetrexed–cisplatin. 
C Additionally, one patient on the placebo arm received 3 cycles which was considered a 
protocol violation. 
D Additionally, one patient in this analysis subpopulation received 7 cycles which was 
considered a protocol violation. Patients in the analysis population who received <6 cycles 
did so due to patient/physician decision or intolerance of study treatment. 
A comparison of the induction tumor response between the two studies (Supplemental Table SI) 
reveals that both studies exhibit a similar distribution of partial tumor response (42–47) and stable 
disease (48–53%) following pemetrexed–cisplatin as first-line therapy. The greater number of 
cycles of pemetrexed–cisplatin given to the JMDB patients (median 6) did not yield appreciably 
more patients with a tumor response (versus SD) than those from the PARAMOUNT study (4 
cycles), nor did it yield a higher disease control rate. 
OS and PFS times for nonsquamous patients treated with pemetrexed and cisplatin in the JMDB 
study were consistent with the results from the placebo arm of the PARAMOUNT study (Fig. 1, 
Table 3). There is no statistical difference between the median OS or PFS of the two groups (PFS 
unadjusted HR = 1.16, 95% CI = 0.96–1.39, p = 0.117; OS unadjusted HR = 1.00, 95% CI = 0.81–1.24, 
p = 0.979). In contrast, the PARAMOUNT pemetrexed continuation maintenance group is not only 
statistically superior to the PARAMOUNT placebo group (as previously reported) [8] and [9], but 
also to the JMDB group, with an unadjusted HR for PFS of 0.66 (95% CI 0.56–0.77), p-value 
<0.00001, and for OS of 0.75 (95% CI 0.63–0.91), p-value = 0.003. Patients receiving pemetrexed 
continuation maintenance therapy after 4 cycles of first-line pemetrexed–cisplatin displayed 
significantly improved PFS and OS over those patients who received only first-line pemetrexed–
cisplatin (median 6 cycles). Survival rates reflected the benefit of pemetrexed maintenance with 
67% and 35% of PARAMOUNT pemetrexed patients surviving to 1-year and 2-years, whereas only 
60% and 25% of PARAMOUNT placebo patients and 59% and 26% of JMDB patients survived to 
those milestones (Table 3). 
 
 Fig. 1.  
Kaplan–Meier plots of overall survival (OS) and progression-free survival (PFS) of 
PARAMOUNT arms and homogeneous JMDB population. (A) OS data are shown for 
PARAMOUNT arms as measured from the start of 4 cycles of pemetrexed–cisplatin 
(induction) treatment followed by randomization to pemetrexed continuation 
maintenance treatment or placebo. JMDB OS data are plotted from the onset of 
pemetrexed–cisplatin treatment (up to 6 cycles). (B) PFS was compared among the three 
populations as calculated to the first date of objectively determined progressive disease or 
death. Patients who had not progressed or died as of the data cutoff date were censored at 
the date of the last tumor assessment. 
Figure options 
Table 3.  
Efficacy summary. 
 
PARAMOUNT 
pemetrexed arm 
(n = 359)a 
PARAMOUNT 
placebo arm 
(n = 180)a 
JMDB homogeneous 
population (n = 346) 
Progression-free survival 
 Number of patients 
with events, n (%) 
331 (92.2) 172 (95.6) 324 (93.6) 
 Number of patients 
censored, n (%) 
28 (7.8) 8 (4.4) 22 (6.4) 
 Median PFS (95% 
CI), months 
7.5 (6.9–8.6) 5.6 (5.5–6.0) 6.2 (5.9–6.5) 
 Comparison with JMDB first-line data 
  Unadjusted log 
rank p-value 
<0.00001 0.117 
 
  Unadjusted HR 
(95% CI) 
0.66 (0.56–0.77) 1.16 (0.96–1.39) 
 
 1-year PFS rate (%) 
29 (24–34) 
Comparison with 
JMDB: p < 0.00001 
10 (6–15) 
Comparison with 
JMDB: p = 0.729 
11 (8–14) 
 2-year PFS rate (%) 
8 (5–11) 
Comparison with 
JMDB: p = 0.009 
4 (2–7) 
Comparison with 
JMDB: p = 0.772 
3 (1–6) 
Overall survival 
 Number of patients 
with events, n (%) 
256 (71.3) 141 (78.3) 225 (65.0) 
 PARAMOUNT 
pemetrexed arm 
(n = 359)a 
PARAMOUNT 
placebo arm 
(n = 180)a 
JMDB homogeneous 
population (n = 346) 
 Number of patients 
censored, n (%) 
103 (28.7) 39 (21.7) 121 (35.0) 
 Median OS (95% CI), 
months 
16.9 (15.8–19.0) 14.0 (12.9–15.5) 14.2 (12.9–15.1) 
 Comparison with JMDB first-line data 
  Unadjusted log 
rank p-value 
0.003 0.979 
 
  Unadjusted HR 
(95% CI) 
0.75 (0.63–0.91) 1.00 (0.81–1.24) 
 
 1-year OS rate (%) 
67 (62–71) 
Comparison with 
JMDB: p = 0.026 
60 (52–67) 
Comparison with 
JMDB: p = 0.789 
59 (53–64) 
 2-year OS rate (%) 
35 (30–40) 
Comparison with 
JMDB: p = 0.026 
25 (19–32) 
Comparison with 
JMDB: p = 0.745 
26 (21–32) 
Abbreviations. CI: confidence interval; HR: hazard ratio; OS: overall survival; PFS: 
progression-free survival. 
A PARAMOUNT PFS and OS data are reported as measured from the beginning of the 
induction cycles. 
Table options 
Since differences in post-discontinuation therapy may impact OS results, Table 4 summarizes data 
for this parameter. Both JMDB and PARAMOUNT specified post-discontinuation therapy to be 
given upon disease progression at the investigator's discretion, with progression assessed 
radiologically every other 3-week cycle. Approximately 60% of patients from the JMDB trial, 64% 
of patients from PARAMOUNT pemetrexed maintenance arm, and 72% of patients from 
PARAMOUNT placebo maintenance arm received another line of systemic post-discontinuation 
therapy. For all three arms, two approved second-line treatments, erlotinib or docetaxel, were 
most frequently prescribed. However, a greater percentage of patients on the PARAMOUNT 
placebo arm received these two treatments, 92%, as compared to 62% of JMDB patients and 73% 
PARAMOUNT pemetrexed maintenance arm. 
Table 4.  
Summary of post-discontinuation systemic therapy. 
 PARAMOUNT 
pemetrexed arm 
(n = 359) 
PARAMOUNT 
placebo arm 
(n = 180) 
JMDB homogeneous 
population 
(n = 346) 
Received any post-
discontinuation therapy, n 
(%) 
231 (64.3) 129 (71.7) 207 (59.8) 
Treatments 
 Erlotinib 142 (39.6) 85 (47.2) 93 (26.9) 
 Docetaxel 121 (33.7) 80 (44.4) 122 (35.3) 
 Gemcitabine 37 (10.3) 16 (8.9) 55 (15.9) 
 Vinorelbine 29 (8.1) 11 (6.1) 41 (11.8) 
 Pemetrexed 8 (2.2) 7 (3.9) 16 (4.6) 
 Gefitinib 3 (0.8) 2 (1.1) 10 (2.9) 
 Other 88 (24.5) 34 (18.9) 133 (38.4) 
Table options 
In order to understand how treatment differences among the trial arms of the PARAMOUNT and 
JMDB studies impacted safety, AEs that emerged after completion of four cycles of first-line 
pemetrexed–cisplatin were examined (Table 5). A greater incidence of toxicities was observed for 
JMDB patients and in PARAMOUNT pemetrexed-treated arm patients than placebo arm patients 
as expected given the additional chemotherapy exposure: a median of two additional 
pemetrexed–cisplatin cycles for the JMDB population and a median of four (range 1–44; 
mean = 7.9, standard deviation 8.3) pemetrexed maintenance cycles for PARAMOUNT patients. 
Grade 3/4 anemia and fatigue, and low grade mucositis/stomatitis, edema, and renal toxicities, as 
well as drug-related serious adverse events, were all higher numerically among PARAMOUNT 
pemetrexed arm patients than JMDB patients in keeping with the greater total number of cycles 
received. Conversely, the incidence of grade 3/4 ototoxicity (inner ear/hearing AE), nausea, and 
vomiting was somewhat higher for the JMDB patients, likely due to the additional cisplatin 
exposure. 
Table 5.  
Drug-related adverse events by maximum CTCAE grade beginning after completion of 4 
cycles of pemetrexed–cisplatin.a 
Adverse eventsb 
PARAMOUNT 
pemetrexed arm 
(n = 359) 
 
PARAMOUNT 
placebo arm 
(n = 180) 
 
JMDB 
homogeneous 
population 
(n = 346) 
 
 
All 
grades 
Grades 3 
and 4 
All 
grades 
Grades 3 
and 4 
All 
grades 
Grades 3 
and 4 
Hematologic toxicities, % 
 Anemia 15.0 5.0 3.3 1.1 9.8 2.9 
 Leukopenia 5.0 2.2 0 0 4.9 0.9 
 Neutropenia 7.5 4.7 0.6 0 8.1 5.2 
 Thrombocytopenia 3.1 1.9 0 0 2.9 1.4 
Non-hematologic toxicities, % 
 Fatigue 16.7 4.7 6.1 1.1 8.1 1.4 
 Mucositis/stomatitis 7.2 0.6 2.2 0 2.0 0.3 
 Edema 6.7 0 2.2 0 1.2 0 
 Nausea 6.7 0.6 1.1 0 8.7 1.4 
 Neuropathy, sensory 5.6 0.6 6.7 0.6 6.9 0 
 Anorexia/decreased 
appetite 
4.2 0.3 1.1 0 3.8 0.6 
 Vomiting 4.2 0.3 0.6 0 5.8 0.9 
 Diarrhea 3.6 0.3 1.7 0 2.9 0 
 Renal toxicities 5.6 1.1 1.7 0 0.6 0 
 Pyrexia 3.1 0 0 0 0 0 
 Ototoxicity 1.4 0 0 0 2.3 0.9 
 Febrile neutropenia 1.4 1.4 0 0 0.3 0.3 
Adverse eventsb 
PARAMOUNT 
pemetrexed arm 
(n = 359) 
 
PARAMOUNT 
placebo arm 
(n = 180) 
 
JMDB 
homogeneous 
population 
(n = 346) 
 
 
All 
grades 
Grades 3 
and 4 
All 
grades 
Grades 3 
and 4 
All 
grades 
Grades 3 
and 4 
Patients with ≥1 drug-
related serious AE, %c 
10.6 4.4 2.9 
Abbreviations. AE: adverse event; CTCAEs: Common Terminology Criteria for Adverse 
Events. 
A Adverse events emerging after the completion of cycle 4 (cycle 5 or later for JMDB, and 
the first maintenance cycle for PARAMOUNT), that are either of special interest or 
occurring in ≥3% of patients (sum of all grades) are listed, with corresponding notation of 
percentage of grades 3 and 4 AEs. JMDB used CTCAE version 2.0, and PARAMOUNT used 
CTCAE version 3.0; hence, the maximum grade in the JMDB study was 4. Grade 5 events 
were possible in PARAMOUNT, but no grade 5 events were reported for any reported term. 
B Some similar terms are combined: renal includes creatinine, glomerular filtration rate, 
renal/genitourinary – other, and renal failure. Fatigue includes asthenia, muscular 
weakness, and lethargy. Edema includes the terms: limb, head and neck, peripheral, and 
localized. Ototoxicity includes the terms: tinnitus, inner ear/hearing, and other 
auditory/hearing. 
cSerious adverse events are defined as adverse events resulting in hospitalization, 
persitent or significant disability/incapacity, or death. 
4. Discussion 
The across-trial comparison of a relevant patient population in the JMDB study with the two arms 
of the PARAMOUNT study presented here support the efficacy of the pemetrexed continuation 
maintenance strategy, and suggests that the results are not influenced by limiting the 
pemetrexed–cisplatin induction treatment to four cycles. 
Analyses of the survival data from the matched study populations showed that results from 
nonsquamous patients treated with pemetrexed–cisplatin in the JMDB first-line study were 
consistent with the results from the PARAMOUNT placebo group. The OS and PFS Kaplan–Meier 
curves of the two groups nearly overlapped, and the tumor responses of the two study 
populations to first-line pemetrexed–cisplatin were statistically indistinguishable. Since the 
homogeneous JMDB patient population received a median of six cycles of pemetrexed/cisplatin 
and the PARAMOUNT placebo patients received four cycles, the approximately two additional 
treatment cycles did not significantly impact survival in this patient population. This result is 
consistent with other studies demonstrating that four cycles of first-line NSCLC treatment is 
sufficient to elicit an efficacy response [15], [16], [17] and [18]. 
As with all cross-trial comparisons, these conclusions should be viewed with caution since the 
trials were performed at different times and in different countries. Indeed, these differences likely 
contributed to the somewhat greater percentage of the PARAMOUNT placebo arm patients who 
received post-study therapy than those in the JMDB population (72% versus 60%), with more of 
the PARAMOUNT placebo patients receiving approved second-line therapy (92% versus 62% 
JMDB). However, in general, about two-thirds of the patients on both studies received another 
line of systemic therapy after discontinuing from the trial, indicating maintenance therapy does 
not substantially alter the likelihood of a patient receiving second-line treatment. 
The PARAMOUNT and JMDB homogeneous populations also differed somewhat with respect to 
two baseline disease characteristics: histology and stage of disease. The higher proportion of 
patients in the JMDB homogenized population with “Other” or “Indeterminate” histology could be 
due to a higher proportion of cytological diagnosis, although recent studies enrolled a similar 
percentage of patients with Other/Indeterminate histology as in JMDB [19] and [20]. For the JMDB 
homogeneous population, a higher percentage of patients with Other/Indeterminate histology 
might imply some prognostic disadvantage, while a greater percentage of patients with disease 
stage IIIb might have provided a prognostic advantage. However, it is unlikely that these small 
imbalances would have introduced much prognostic heterogeneity into the cross-trial comparison, 
especially since patients with early disease progression were excluded from both PARAMOUNT 
and the JMDB homogeneous population. The similarity of outcomes between the JMDB 
homogeneous population and the PARAMOUNT control arm supports this conclusion. 
Additional analyses found that PARAMOUNT pemetrexed continuation maintenance arm had 
statistically superior PFS and OS compared with the JMDB homogeneous population [unadjusted 
HRs: PFS 0.66 (0.56–0.77, p < 0.00001); OS 0.75 (0.63–0.91, p = 0.003)]. This result indicates a 
relative advantage of pemetrexed maintenance therapy immediately following four cycles of first-
line pemetrexed–cisplatin versus up to six cycles of first-line pemetrexed–cisplatin followed by a 
watch-and-wait strategy, with patients in both groups having the option of second-line treatment 
upon progression. The Kaplan–Meier plots show greater separation of the OS and PFS curves on 
the latter portion of the curve, suggesting that more benefit is gained by patients who receive a 
greater number of maintenance cycles, and further supporting the hypothesis that six cycles of 
platin-based chemotherapy may not be as effective as four cycles followed by single-agent 
continuation maintenance. As expected, the greater chemotherapy exposure entailed somewhat 
greater incidence of toxicities on the PARAMOUNT maintenance pemetrexed arm than for the 
JMDB population, including anemia and fatigue. Furthermore, both the PARAMOUNT pemetrexed 
arm and the JMDB homogeneous group had greater incidence of toxicities than the PARAMOUNT 
placebo arm. However, the overall incidence of all grades and grade 3/4 toxicities emerging after 
four cycles of pemetrexed–cisplatin was low for both PARAMOUNT and JMDB (≤16.7% and ≤5.2%, 
respectively), and the toxicities were consistent with the known safety profile of pemetrexed–
cisplatin [5], [6] and [21]. 
The superiority of the maintenance approach is likely due to a number of factors. First, it prolongs 
the administration of a drug shown to be well tolerated and effective during the administration of 
the platinum-based induction doublet. Additionally, it offers the improved safety of a single-agent 
treatment. Finally, the maintenance approach ensures that patients receive additional therapy. 
Recent reviews of the maintenance approach have underscored this advantage, noting that many 
factors including performance status deterioration often prevent patients from receiving second-
line therapy at the time of disease progression [22] and [23]. 
To summarize, this cross-trial comparison showed that the PARAMOUNT placebo arm results are 
consistent with the JMDB homogeneous group treated with pemetrexed–cisplatin. The similar 
magnitude of the JMDB and PARAMOUNT placebo results suggests four cycles of pemetrexed–
cisplatin yield maximal efficacy if a patient is to stop treatment until progression. However, 
additional results reveal that the most efficacious of the treatments was four cycles of 
pemetrexed–cisplatin followed by pemetrexed continuation maintenance. While this regimen 
increased some grade 3/4 toxicities (as did the additional cycles of pemetrexed/cisplatin in the 
JMDB population), the overall incidence of toxicities remained low. Overall, these data support the 
efficacy of first-line pemetrexed–cisplatin therapy for nonsquamous NSCLC as first identified in the 
landmark JMDB study, and support the administration of maintenance pemetrexed after the first-
line treatment. 
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